氯吡格雷联合拜阿司匹林治疗高龄急性脑梗死病人效果

袁凤云; 刘岩红

doi:10.13898/j.cnki.issn.1000-2200.2019.06.019

氯吡格雷联合拜阿司匹林治疗高龄急性脑梗死病人效果

Effect of clopidogrel complicated with biaspion in the treatment of acute cerebral infarction

摘要

摘要:
目的探讨拜阿司匹林联合氯吡格雷治疗高龄急性脑梗死的效果，及其对α颗粒膜糖蛋白（CD62p）及溶酶体颗粒膜糖蛋白（CD63）表达的影响。
方法选取高龄急性脑梗死病人118例，按照随机数字表法分为观察组60例和对照组58例。对组组病人给予拜阿司匹林150 mg，每天1次口服；观察组给予拜阿司匹林100 mg+氯吡格雷50 mg，每天1次口服。使用流式细胞术检测2组病人治疗前后的CD62p、CD63阳性率，同时进行临床疗效评定。
结果2组病人治疗前CD62p和CD63阳性率差异均无统计学意义（P>0.05），治疗后1周与治疗前差异无统计学意义（P>0.05），治疗后2周与治疗前、治疗后3周与治疗后2周的CD62p、CD63和NIHSS评分差异均有统计学意义（P < 0.01）。2组病人不良事件总发生率差异无统计学意义（P>0.05）。
结论拜阿司匹林100 mg+氯吡格雷50 mg治疗高龄脑梗死病人的总体疗效比单用拜阿司匹林150 mg疗效好，CD63、CD62p的监测可以成为抗血小板治疗效果的重要参考指标。

Abstract:
ObjectiveTo explore the effects of clopidogrel complicated with biaspion in the treatment of acute cerebral infarction, and on the expression levels of alpha granule membrane glycoprotein(CD62p) and lysosomal granule membrane glycoprotein(CD63).
MethodsThe positive rates of CD62p and CD63 in two groups were detected before and after treatment, and the clinical efficacy was evaluated.
ResultsThe differences of the positive rates of CD62p and CD63 between two groups before treatment were not statistically significant(P>0.05), and the differences of the positive rates of CD62p and CD63 in two groups between before treatment and after 1 week of treatment were not statistically significant(P>0.05).The differences of CD62p, CD63 and NIHSS scores in two groups between after and before treatment, and between after 3 and 2 weeks of treatment were statistically significant(P < 0.01).There was no statistical significance in total incidence rate of adverse event between two groups(P>0.05).
ConclusionsThe overall efficacy of 100 mg baiaspirin combined with 50 mg clopidogrel in the treatment of cerebral infarction of elderly patients is better than that of 150 mg baiaspirin.The monitoring of CD63 and CD62p can be an important index for anti-platelet therapy.

HTML全文

参考文献(16)

施引文献

资源附件(0)